Research progress of finelidone in treatment of type 2 diabetic nephropathy
Diabetic kidney disease(DKD)is one of the complications of diabetic microangiopathemia,which is characterized by proteinuria and decreased glomerular filtration function.It is also the most common cause of chronic kidney disease(CKD).Its incidence is high and the prognosis is poor.The current clinical treatment regimen can improve proteinuria to a certain extent and delay the progression of the disease,but there is still a large residual risk,and there is still a long distance to reduce the risk of ERSD and CVD.Finelidone is a new type of nonsteroidal salt corticosteroid,which has higher selectivity and safety compared with traditional salt corticoreceptor antagonists,and can reduce the risk of renal adverse events.This article reviews the mechanism of action,effectiveness and safety of finelidone in the treatment of type 2 diabetic nephropathy from multiple perspectives,aiming to provide new ideas and evidence support for the treatment of DKD.
NETL
NSTL
万方数据
